CYP1B1 and neoplasm: The presence of metabolically active CYP1B1, which is overexpressed in tumours and which is capable of metabolising anticancer drugs within the tumour cells offers tremendous opportunities for the development of novel prodrugs activated by CYP1B1 only in the tumour cells (Murray et al, 2001; Patterson and Murray, 2002).